Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer

Curium announced that patients in the Czech Republic and Slovakia received the first doses of diagnostic radiopharmaceuticals used to indicate the detection of prostate-specific membrane antigen-positive lesions with positron emission tomography in patients with prostate cancer.